Xuanzhu Biotechnology-B (02575) proposed to implement the full circulation of H shares and submit it to the China Securities Regulatory Commission for record.

Finance and Economics App News: Xuanzhu Bio-B (02575) announced that on November 17, 2025, the company has submitted an application for record filing to the China Securities Regulatory Commission. The application is related to the proposal to implement full circulation of H shares, converting a total of 357,245,794 unlisted shares into H shares at a one-to-one ratio. After completing all record filing requirements (including filing with the China Securities Regulatory Commission) and obtaining all relevant approvals (including approval from the Hong Kong Stock Exchange for conversion and listing), and complying with all applicable laws, regulations, and rules, the 357,245,794 unlisted shares will be converted into 357,245,794 H shares and will be listed and traded on the Hong Kong Stock Exchange.